Hepatitis E virus replication requires an active ubiquitin-proteasome system

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5948-5952

  Karpe, Yogesh A ^a   Meng, Xiang Jin ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CAPSID PROTEIN; EPOXOMICIN; GREEN FLUORESCENT PROTEIN; LACTACYSTIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; RENILLA LUCIFERIN 2 MONOOXYGENASE; UBIQUITIN; UBIQUITIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HEPATITIS E; HEPATITIS E VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RLUC GENE; VIRUS CAPSID; VIRUS GENE; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

CELL LINE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; UBIQUITIN; VIRUS REPLICATION;

HEPATITIS E VIRUS;

EID: 84861309346     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07039-11     Document Type: Article

References (51)

1. Agrawal S, Gupta D, Panda SK. 2001. The 3' end of hepatitis E virus (HEV) genome binds specifically to the viral RNA polymerase (RdRp). Virology 282:87-101.
2. Arankalle VA, et al. 1994. Seroepidemiology of water-borne hepatitis in India and evidence for a third enterically-transmitted hepatitis agent. Proc. Natl. Acad. Sci. U. S. A. 91:3428-3432.
3. Burch AD, Weller SK. 2004. Nuclear sequestration of cellular chaperone and proteasomal machinery during herpes simplex virus type 1 infection. J. Virol. 78:7175-7185.
4. Cao D, Huang YW, Meng XJ. 2010. The nucleotides on the stem-loop RNA structure in the junction region of the hepatitis E virus genome are critical for virus replication. J. Virol. 84:13040-13044.
5. Chandra V, Kar-Roy A, Kumari S, Mayor S, Jameel S. 2008. The hepatitis E virus ORF3 protein modulates epidermal growth factor receptor trafficking, STAT3 translocation, and the acute-phase response. J. Virol. 82:7100-7110.
6. Chandra V, Kalia M, Hajela K, Jameel S. 2010. The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the Cbl-CIN85 complex. J. Virol. 84:3857-3867.
7. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. 2011. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future prospective. Current Cancer Drug Target 11:23953.
8. Cordoba L, et al. 2011. Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation. J. Virol. 85:5338-5349.
9. Delboy MG, Roller DG, Nicola AV. 2008. Cellular proteasome activity facilitates herpes simplex virus entry at a postpenetration step. J. Virol. 82:3381-3390.
10. Edelmann MJ, Benjamin N, Kessler BM. 2011. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev. Mol. Med. 13:e35.
11. Emerson SU, Purcell RH. 2003. Hepatitis E virus. Rev. Med. Virol. 13: 145-154.
12. Emerson SU, et al. 2004. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J. Virol. 78:4838-4846.
13. Emerson SU, Nguyen H, Torian U, Purcell RH. 2006. ORF3 protein of hepatitis E virus is not required for replication, virion assembly, or infection of hepatoma cells in vitro. J. Virol. 80:10457-10464.
14. Emerson SU, et al. 2010. Release of genotype 1 hepatitis E virus from cultured hepatoma and polarized intestinal cells depends on open reading frame 3 protein and requires an intact PXXP motif. J. Virol. 84:9059-9069.
15. Graff J, Torian U, Nguyen H, Emerson SU. 2006. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J. Virol. 80:5919-5926.
16. Graff J, et al. 2008. Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J. Virol. 82:1185-1194.
17. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-479.
18. Ichiyama K, et al. 2009. Determination of the 5'-terminal sequence of subgenomic RNA of hepatitis E virus strains in cultured cells. Arch. Virol. 154:1945-1951.
19. Isaacson MK, Ploegh HL. 2009. Ubiquitination, ubiquitin-like modifiers, and deubiquitination in viral infection. Cell Host Microbe 5:559-570.
20. Kabrane-Lazizi Y, Meng XJ, Purcell RH, Emerson SU. 1999. Evidence that the genomic RNA of hepatitis E virus is capped. J. Virol. 73:8848-8850.
21. Karpe YA, Lole KS. 2010. NTPase and 5' to 3' RNA duplex-unwinding activities of hepatitis E virus helicase domain. J. Virol. 84:3595-3602.
22. Karpe YA, Lole KS. 2010. RNA 5' triphosphatase activity associated with hepatitis E virus helicase domain. J. Virol. 84:9637-9641.
23. Karpe YA, Lole KS. 2011. Deubiquitinating activity associated with hepatitis E virus putative papain like cysteine protease. J. Gen. Virol. 92:2088-2092.
24. Kar-Roy A, Korkaya H, Oberoi R, Lal SK, Jameel S. 2004. The hepatitis E virus open reading frame 3 protein activates ERK through binding and inhibition of the MAPK phosphatase. J. Biol. Chem. 279:28345-28357.
25. Koonin EV, et al. 1992. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proc. Natl. Acad. Sci. U. S. A. 89:8259-8263.
26. Korkaya H, et al. 2001. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. J. Biol. Chem. 276:42389-42400.
27. Kouroukis CT, et al. 2011. A phase II study of bortezomib and gemeitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada clinical trial group (IND 172). Leuk. Lymphoma 52:394-399.
28. Lopez T, Silvia-Ayala D, Lopez S, Arias CA. 2011. Replication of the rotavirus genome requires an active ubiquitin-proteasome system. J. Virol. 85:11964-11971.
29. Magden J, et al. 2001. Virus-specific mRNA capping enzyme encoded by hepatitis E virus. J. Virol. 75:6249-6255.
30. Meng XJ. 2010. Recent advances in hepatitis E virus. J. Viral Hepat. 17: 153-161.
31. Meng XJ. 2011. From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety. Virus Res. 161:23-30.
32. Meng XJ, et al. 2011. Hepeviridae, p 1021-1028. In King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (ed), Virus taxonomy, 9th report of the International Committee on Taxonomy of Viruses. Elsevier Academic Press, London, England.
33. Moin SM, Panteva M, Jameel S. 2007. The hepatitis E virus ORF3 protein protects cells from mitochondrial depolarization and death. J. Biol. Chem. 282:21124-21133.
34. Moin SM, Chandra V, Arya R, Jameel S. 2009. The hepatitis E virus ORF3 protein stabilizes HIF-1α and enhances HIF-1-mediated transcriptional activity through p300/CBP. Cell. Microbiol. 11:1409-1421.
35. Ratra R, Kar-Roy A, Lal SK. 2008. The ORF3 protein of hepatitis E virus interacts with hemopexin by means of its 26 amino acid N-terminal hydrophobic domain II. Biochemistry 47:1957-1969.
36. Satheshkumar PS, Anton LC, Sanz P, Moss B. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
37. Schmitt AP, Leser GP, Morita E, Sundquist WI, Lamb RA. 2005. Evidence for a new viral late-domain core sequence, FPVI, necessary for budding of a paramyxovirus. J. Virol. 79:2988-2997.
38. Schubert U, et al. 2000. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc. Natl. Acad. Sci. U. S. A. 97:13057-13062.
39. Tam AW, et al. 1991. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185:120-131.
40. Tanahashi N, Kawahara H, Murakami Y, Tanaka K. 1999. The proteasome-dependent proteolytic system. Mol. Biol. Rep. 26:3-9.
41. Thakral D, Nayak B, Rahman S, Durgapal H, Panda SK. 2005. Replication of recombinant hepatitis E virus genome tagged with reporter gene and generation of short-term cell line producing viral RNA and proteins. J. Gen. Virol. 86:1189-1200.
42. Tran K, Mahr JA, Spector DH. 2010. Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription. J. Virol. 84:3079-3093.
43. Tyagi S, Korkaya H, Zafrullah M, Jameel S, Lal SK. 2002. The phosphorylated form of the ORF3 protein of hepatitis E virus interacts with its non-glycosylated form of the major capsid protein, ORF2. J. Biol. Chem. 277:22759-22767.
44. 1-microglobulin/bikunin precursor (AMBP) and expedites their export from the hepatocyte. J. Biol. Chem. 279:29308-29319.
45. Tyagi S, Surjit M, Lal SK. 2005. The 41-amino-acid C-terminal region of the hepatitis E virus ORF3 protein interacts with bikunin, a kunitz-type serine protease inhibitor. J. Virol. 79:12081-12087.
46. Voges D, Zwickl P, Baumeister W. 1999. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68:1015-1068.
47. Widjaja I, et al. 2010. Inhibition of the ubiquitin proteasome system affects influenza A virus infection at a postfusion step. J. Virol. 84:9625-9631.
48. Yamada K, et al. 2009. ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J. Gen. Virol. 90:1880-1891.
49. Zafrullah M, Ozdener MH, Panda SK, Jameel S. 1997. The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. J. Virol. 71:9045-9053.
50. Zafrullah M, Ozdener MH, Kumar R, Panda SK, Jameel S. 1999. Mutational analysis of glycosylation, membrane translocation, and cell surface expression of the hepatitis E virus ORF2 protein. J. Virol. 73:4074-4082.
51. Zhang Z, et al. 2000. Structural and functional characterization of interaction between hepatitis B virus X protein and the proteasome complex. J. Biol. Chem. 275:15157-15165.